News Brief

CLN Banner Logo

June 2014 Clinical Laboratory News: Volume 40, Number 6


Microbiology, Advanced Tests Projected to Keep U.S. IVD Market Afloat

Although cuts to lab reimbursement and other variables have dampened the growth of the U.S. in vitro diagnostics (IVD) market, its microbiology and advanced testing segments are still projected to experience above-average market development through 2018. Those were among the findings of “The United States Market for In Vitro Diagnostic Tests,” a report by Kalorama Information analyst Emil Salazar. Kalorama reached this conclusion by comparing each IVD market segment’s actual or projected monetary share of IVD market volume between 2013 and 2018 with the segment’s current share of the market.

Advanced tests in particular are expected to boom, with molecular assays for non-infectious diseases testing and histology projected to be the two fastest growing IVD market segments through 2018. This is because the use of histology to support cancer diagnosis and treatment is becoming increasingly reliant on immunohistochemical reagents and molecular hybridization techniques. Additionally, the U.S. is ground zero for an influx of advanced molecular assays for blood-based cancer testing, circulating tumor cell testing, pharmacodiagnostics, and other sequencing-based tests.

Several factors have also kept market growth robust for microbiology diagnostics. These include, among others, hospital investment in microbiology for healthcare-acquired infection testing and market penetration by higher-priced molecular infectious diseases tests.

On the downside, Kalorama projected below-average market development in the next 5 years in both the core lab and point of care IVD market segments. However, the report states that several factors such as continued product innovation will lend stability and growth to IVD sales overall.

  The full report is available for purchase at http://www.kaloramainformation.com/United-States-Vitro-8079142/.

Page Access:
Interactive Digital Edition